This is the same indication where the Europe’s CHMP approved Xarelto two weeks ago (#msg-80711606). JNJ is Bayer's partner on Xarelto in the US market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.